Frontiers in cardiovascular medicine · 2026
Analysis of the association between SLCO1B1 gene polymorphisms and coronary heart disease risk in southern Han Chinese population and statin responses in the elderly.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Long Youmin, Liang Yanling, Lin Chuying, Liang Guangtie, Li Guohao, Li Zhuoran, Lei Xiuxia
Аннотация
OBJECTIVE: Research on SLCO1B1 polymorphisms and statin therapy in elderly patients is limited and controversial. This study explored the association of SLCO1B1 c.521T>C and c.388A>G variants with coronary heart disease (CHD) risk, and evaluated the lipid-lowering efficacy and safety of standard-dose statins in subjects aged >75 years to provide evidence for geriatric clinical statin use.
METHODS: A retrospective cohort study analyzed 6,146 individuals who were genotyped SLCO1B1 variants c.521T>C and c.388A>G. 2318 participants were selected to evaluate the prevalence of diseases. 118 subjects (>75 years) were categorized into statin-treated (n = 57) and control (n = 61) groups. Lipid indices, liver function tests and muscle injury marker were measured by standard techniques.
RESULTS: The SLCO1B1 c.521C allele was independently associated with increased CHD risk (odds ratio [OR] = 1.37, 95% CI:1.06-1.77, P = 0.02). Statin therapy significantly reduced total cholesterol (TC: 3.70 ± 0.88 vs. 4.18 ± 0.84 mmol/L, P = 0.004) and low-density lipoprotein cholesterol (LDL-C: 1.88 ± 0.70 vs. 2.17 ± 0.61 mmol/L, P = 0.04) without elevating hepatic transaminases or creatine kinase (P > 0.05). Carriers of the c.388A allele exhibited greater TC/LDL-C reductions compared to c.388GG homozygotes (P < 0.05), whereas the c.521T > C polymorphism showed no significant impact on therapeutic efficacy or safety outcomes.
CONCLUSIONS: The SLCO1B1 c.521C allele represents an independent genetic marker for CHD susceptibility in the southern Han Chinese population. In geriatric populations, standard-dose statin therapy maintains lipid-lowering efficacy and safety, unaffected by the SLCO1B1 c.521T>C polymorphism. Our findings provide a genetic screening tool for the primary prevention of cardiovascular diseases and offer support for the efficacy and safety of statin-based lipid-lowering therapy in adults aged >75 years.
METHODS: A retrospective cohort study analyzed 6,146 individuals who were genotyped SLCO1B1 variants c.521T>C and c.388A>G. 2318 participants were selected to evaluate the prevalence of diseases. 118 subjects (>75 years) were categorized into statin-treated (n = 57) and control (n = 61) groups. Lipid indices, liver function tests and muscle injury marker were measured by standard techniques.
RESULTS: The SLCO1B1 c.521C allele was independently associated with increased CHD risk (odds ratio [OR] = 1.37, 95% CI:1.06-1.77, P = 0.02). Statin therapy significantly reduced total cholesterol (TC: 3.70 ± 0.88 vs. 4.18 ± 0.84 mmol/L, P = 0.004) and low-density lipoprotein cholesterol (LDL-C: 1.88 ± 0.70 vs. 2.17 ± 0.61 mmol/L, P = 0.04) without elevating hepatic transaminases or creatine kinase (P > 0.05). Carriers of the c.388A allele exhibited greater TC/LDL-C reductions compared to c.388GG homozygotes (P < 0.05), whereas the c.521T > C polymorphism showed no significant impact on therapeutic efficacy or safety outcomes.
CONCLUSIONS: The SLCO1B1 c.521C allele represents an independent genetic marker for CHD susceptibility in the southern Han Chinese population. In geriatric populations, standard-dose statin therapy maintains lipid-lowering efficacy and safety, unaffected by the SLCO1B1 c.521T>C polymorphism. Our findings provide a genetic screening tool for the primary prevention of cardiovascular diseases and offer support for the efficacy and safety of statin-based lipid-lowering therapy in adults aged >75 years.